Related Experiment Videos
[Hepatic changes in different hormone replacement therapies in climacteric]
Zentralblatt Fur Gynakologie
|January 1, 1995
Summary
Hormone replacement therapy showed no adverse effects on liver enzymes in postmenopausal women. Liver enzyme levels (ASAT, ALAT, GGT, AP) decreased during treatment, with transdermal therapy not increasing SHBG.
Area of Science:
- Endocrinology
- Hepatology
- Women's Health
Background:
- Hormone replacement therapy (HRT) is used for menopausal symptoms.
- Liver enzymes and sex hormone-binding globulin (SHBG) are key health indicators.
- Understanding HRT's impact on liver function is crucial for patient safety.
Purpose of the Study:
- To evaluate the effects of different HRT regimens on liver enzymes.
- To assess changes in SHBG levels during HRT.
- To determine if transdermal HRT impacts SHBG differently.
Main Methods:
- 128 postmenopausal women participated in a 12-month study.
- Measurements included aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl transferase (GGT), alkaline phosphatase (AP), and SHBG.
- Participants underwent various hormone replacement therapies.
Main Results:
- No negative impact on ASAT, ALAT, GGT, or AP was observed.
- Liver enzyme levels (ASAT, ALAT, GGT, AP) showed a decrease over the 12 months.
- Transdermal HRT did not lead to elevated SHBG levels compared to other methods.
Conclusions:
- HRT is safe concerning liver enzyme levels in postmenopausal women.
- A decrease in liver enzymes suggests potential benefits or adaptation during HRT.
- Transdermal HRT appears to have a neutral effect on SHBG levels.